Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Hemorrhage, Surgical, Tonsillar Bleeding
Interventions: Tranexamic Acid Injectable Product, Normal Saline; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Davis, California • Providence, Rhode Island • San Antonio, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab 10 mg/kg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more

Conditions: Osteoporosis, Spinal Cord Injury
Interventions: Denosumab, Placebo (identical Denosumab volume of normal saline); Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Osteoporosis
Interventions: Risedronate, Parathyroid Hormone; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Kidney Disease, Pediatric Urology
Interventions: NSAIDs, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Months to 25 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pleural Effusion, Single-ventricle
Interventions: Vasopressin, Normal Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Months to 7 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Atrial Fibrillation
Interventions: HBI-3000, Placebo; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more

Conditions: Osteoarthritis of the Knee
Interventions: Amniotic Fluid 4.0ml dose, Amniotic Fluid 2.0ml dose, Placebo Control; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Des Plaines, Illinois

Conditions: Systemic Allergic Reaction
Interventions: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post COVID-19 Condition, Long COVID
Interventions: Rintatolimod, Placebo / Normal Saline; Drug · Other
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Canoga Park, California • Inglewood, California • San Diego, California + 2 more

Conditions: Osteoarthritis, Knee
Interventions: Acellular Amniotic Membrane Derived Allograft Injection (NuDYN); Other
Lead sponsor: Illinois Center for Orthopaedic Research and Education; Other
Eligibility: 21 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Westmont, Illinois

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Cancer, Tumour, Surgery
Interventions: Tranexamic acid (TXA), Normal saline; Drug
Lead sponsor: Sunnybrook Health Sciences Centre; Other
Eligibility: 18 Years and older
Enrollment: 1,386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions: WAL0921, Placebo; Drug
Lead sponsor: Walden Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more

Conditions: Placenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid
Interventions: Tranexamic Acid, Placebo Drug; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fresno, California

Conditions: COVID, COVID-19, Corona Virus Infection
Interventions: Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo; Drug
Lead sponsor: BayCare Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Clearwater, Florida • St. Petersburg, Florida • Tampa, Florida

Conditions: Cognitive Decline
Interventions: Lidocaine, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Durham, North Carolina • Norfolk, Virginia

Conditions: Pelvic Organ Prolapse
Interventions: IV Acetaminophen, IV normal saline; Drug
Lead sponsor: Halina M Zyczynski, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: zodasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Breast Neoplasms
Interventions: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more

Conditions: Functional Iron Deficiency, Trauma, Anemia
Interventions: Iron sucrose, Oxandrolone, IV iron placebo, Oxandrolone placebo; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Brow Ptosis, Facial Scarring
Interventions: 5-Fluorouracil, Normal Saline Flush, 0.9% Injectable Solution; Drug
Lead sponsor: Eyelid and Facial Consultants; Other
Eligibility: 40 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Houma, Louisiana • New Orleans, Louisiana

Conditions: Fractures, Open
Interventions: Tobramycin, Placebo: normal saline; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Search by objective public record fields.

TEAPOT Study Multisite

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

Denosumab Administration After Spinal Cord Injury

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

Safety of Short-course of NSAIDs in Pediatric Patients With CKD

Use of Vasopressin Following the Fontan Operation

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Evaluation of Amniotic Fluid Product in Knee Osteoarthritis

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

An Amniotic Membrane Injection Comparing Two Doses (1 mL and 2 mL Injection) and a Placebo (Sterile Saline) in the Treatment of Osteoarthritis of the Knee

Denosumab for Type 1 Diabetes

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

Lidocaine For Neuroprotection During Cardiac Surgery

IV Acetaminophen for Postoperative Pain After Pelvic Organ Prolapse Repair

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone

The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair

Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19